Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investi- gators. N Engl J Med. 1996;335:1001 9. 396. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cho- lesterol levels. The Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349 57. 397. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorva- statin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70 6. 398. MRC-BHF Heart Protection Study of cholesterol lowering with sim- vastatin in 20,536 high-risk individuals: a randomised placebocon- trolled trial. Lancet. 2002;360:7 22. 399. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20 8. 400. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. 401. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164:1427 36. 402. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 97. 403. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578 81. 404. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257 62. 405. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350:461 8. 406. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation. 2004;110:1213 8. 407. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359: 677 87. at AHA National Center on February 11, 2014 http://circ.ahajournals.org/ Downloaded from 358. Harris PJ, Harrell FE Jr, Lee KL, et al. Survival in medically treated coronary artery disease. Circulation. 1979;60:1259 69. 359. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol. 1986;7: 464 71. 360. Marwick TH, Mehta R, Arheart K, et al. Use of exercise echocardiog- raphy for prognostic evaluation of patients with known or suspected coronary artery disease. J Am Coll Cardiol. 1997;30:83 90. 361. Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardiovas- cular death in men undergoing noninvasive evaluation for coronary artery disease. Ann Intern Med. 1993;118:689 95. 362. Stratmann HG, Williams GA, Wittry MD, et al. Exercise technetium- 99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. Circulation. 1994;89:615 22. 363. Miller TD, Christian TF, Taliercio CP, et al. Impaired left ventricular function, one- or two-vessel coronary artery disease, and severe ische- mia: outcome with medical therapy versus revascularization. Mayo Clin Proc. 1994;69:626 31. 364. Emond M, Mock MB, Davis KB, et al. Long-term survival of med- ically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645 57. 365. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circu- lation. 1983;68:785 95. 366. Boden WE, O Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503 16. 367. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation. 1983;68:951 60. 368. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1996;335:217 25. 369. Leape LL, Park RE, Bashore TM, et al. Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures. Am Heart J. 2000;139:106 13. 370. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myo- cardial infarction. J Am Coll Cardiol. 1988;12:56 62. 371. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157 66. 372. Braunwald E. Epilogue: what do clinicians expect from imagers? J Am Coll Cardiol. 2006;47:C101 C103. 373. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Adminis- tration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med. 1984;311:1333 9. 374. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angio- graphic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854 66. 375. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 1990;82:1629 46. 376. Gersh BJ, Califf RM, Loop FD, et al. Coronary bypass surgery in chronic stable angina. Circulation. 1989;79:I46 I59. 377. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994;89:2015 25. 378. Califf RM, Phillips HR, III, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol. 1985;5:1055 63. 379. Nakagomi A, Celermajer DS, Lumley T, et al. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol. 1996;78:516 9. 380. Campeau L, Corbara F, Crochet D, et al. Left main coronary artery stenosis: the influence of aortocoronary bypass surgery on survival. Circulation. 1978;57:1111 5. 381. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2325 34. 382. Conley MJ, Ely RL, Kisslo J, et al. The prognostic spectrum of left main stenosis. Circulation. 1978;57:947 52. 383. Cameron A, Kemp HG Jr, Fisher LD, et al. Left main coronary artery stenosis: angiographic determination. Circulation. 1983;68:484 9. 384. Isner JM, Kishel J, Kent KM, et al. Accuracy of angiographic deter- mination of left main coronary arterial narrowing. Angiographic histologic correlative analysis in 28 patients. Circulation. 1981;63: 1056 64. 385. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ische- mic heart disease. Circulation. 1995;92:2333 42. 386. West JN, Bennett MR, Pentecost BL. Association of transient abnormal Q-waves during exercise testing with a stenosis of the main stem of the left coronary artery. Int J Cardiol. 1991;31:102 4. 387. Gibbons RJ, Fyke FE, III, Brown ML, et al. Comparison of exercise performance in left main and three-vessel coronary artery disease. Cathet Cardiovasc Diagn. 1991;22:14 20. 388. Janosi A, Vertes A. Exercise testing and left main coronary artery stenosis. Can patients with left main disease be identified? Chest. 1991;100:227 9. 389. Morris SN, Phillips JF, Jordan JW, et al. Incidence and significance of decreases in systolic blood pressure during graded treadmill exercise testing. Am J Cardiol. 1978;41:221 6. 390. Plotnick GD, Greene HL, Carliner NH, et al. Clinical indicators of left main coronary artery disease in unstable angina. Ann Intern Med. 1979;91:149 53. 391. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980 2000. N Engl J Med. 2007;356: 2388 98. 392. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937 52. 393. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706 17. 394. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 395. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investi- gators. N Engl J Med. 1996;335:1001 9. 396. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cho- lesterol levels. The Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349 57. 397. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorva- statin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70 6. 398. MRC-BHF Heart Protection Study of cholesterol lowering with sim- vastatin in 20,536 high-risk individuals: a randomised placebocon- trolled trial. Lancet. 2002;360:7 22. 399. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20 8. 400. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. 401. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164:1427 36. 402. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 97. 403. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578 81. 404. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257 62. 405. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350:461 8. 406. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation. 2004;110:1213 8. 407. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359: 677 87. at AHA National Center on February 11, 2014 http://circ.ahajournals.org/ Downloaded from 358. Harris PJ, Harrell FE Jr, Lee KL, et al. Survival in medically treated coronary artery disease. Circulation. 1979;60:1259 69. 359. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol. 1986;7: 464 71. 360. Marwick TH, Mehta R, Arheart K, et al. Use of exercise echocardiog- raphy for prognostic evaluation of patients with known or suspected coronary artery disease. J Am Coll Cardiol. 1997;30:83 90. 361. Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardiovas- cular death in men undergoing noninvasive evaluation for coronary artery disease. Ann Intern Med. 1993;118:689 95. 362. Stratmann HG, Williams GA, Wittry MD, et al. Exercise technetium- 99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. Circulation. 1994;89:615 22. 363. Miller TD, Christian TF, Taliercio CP, et al. Impaired left ventricular function, one- or two-vessel coronary artery disease, and severe ische- mia: outcome with medical therapy versus revascularization. Mayo Clin Proc. 1994;69:626 31. 364. Emond M, Mock MB, Davis KB, et al. Long-term survival of med- ically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645 57. 365. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circu- lation. 1983;68:785 95. 366. Boden WE, O Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503 16. 367. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation. 1983;68:951 60. 368. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1996;335:217 25. 369. Leape LL, Park RE, Bashore TM, et al. Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures. Am Heart J. 2000;139:106 13. 370. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myo- cardial infarction. J Am Coll Cardiol. 1988;12:56 62. 371. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157 66. 372. Braunwald E. Epilogue: what do clinicians expect from imagers? J Am Coll Cardiol. 2006;47:C101 C103. 373. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Adminis- tration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med. 1984;311:1333 9. 374. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angio- graphic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854 66. 375. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 1990;82:1629 46. 376. Gersh BJ, Califf RM, Loop FD, et al. Coronary bypass surgery in chronic stable angina. Circulation. 1989;79:I46 I59. 377. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994;89:2015 25. 378. Califf RM, Phillips HR, III, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol. 1985;5:1055 63. 379. Nakagomi A, Celermajer DS, Lumley T, et al. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol. 1996;78:516 9. 380. Campeau L, Corbara F, Crochet D, et al. Left main coronary artery stenosis: the influence of aortocoronary bypass surgery on survival. Circulation. 1978;57:1111 5. 381. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2325 34. 382. Conley MJ, Ely RL, Kisslo J, et al. The prognostic spectrum of left main stenosis. Circulation. 1978;57:947 52. 383. Cameron A, Kemp HG Jr, Fisher LD, et al. Left main coronary artery stenosis: angiographic determination. Circulation. 1983;68:484 9. 384. Isner JM, Kishel J, Kent KM, et al. Accuracy of angiographic deter- mination of left main coronary arterial narrowing. Angiographic histologic correlative analysis in 28 patients. Circulation. 1981;63: 1056 64. 385. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ische- mic heart disease. Circulation. 1995;92:2333 42. 386. West JN, Bennett MR, Pentecost BL. Association of transient abnormal Q-waves during exercise testing with a stenosis of the main stem of the left coronary artery. Int J Cardiol. 1991;31:102 4. 387. Gibbons RJ, Fyke FE, III, Brown ML, et al. Comparison of exercise performance in left main and three-vessel coronary artery disease. Cathet Cardiovasc Diagn. 1991;22:14 20. 388. Janosi A, Vertes A. Exercise testing and left main coronary artery stenosis. Can patients with left main disease be identified? Chest. 1991;100:227 9. 389. Morris SN, Phillips JF, Jordan JW, et al. Incidence and significance of decreases in systolic blood pressure during graded treadmill exercise testing. Am J Cardiol. 1978;41:221 6. 390. Plotnick GD, Greene HL, Carliner NH, et al. Clinical indicators of left main coronary artery disease in unstable angina. Ann Intern Med. 1979;91:149 53. 391. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980 2000. N Engl J Med. 2007;356: 2388 98. 392. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937 52. 393. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706 17. 394. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 395. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investi- gators. N Engl J Med. 1996;335:1001 9. 396. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cho- lesterol levels. The Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349 57. 397. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorva- statin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70 6. 398. MRC-BHF Heart Protection Study of cholesterol lowering with sim- vastatin in 20,536 high-risk individuals: a randomised placebocon- trolled trial. Lancet. 2002;360:7 22. 399. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20 8. 400. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. 401. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164:1427 36. 402. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 97. 403. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578 81. 404. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257 62. 405. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350:461 8. 406. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation. 2004;110:1213 8. 407. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359: 677 87. 408. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360:2503 15. 409. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of dif- ferent treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mor- tality and myocardial infarction. Circulation. 2009;120:2529 40. 410. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364: 1607 16. 411. Pittman MA, Margolin FS. Community health. Crossing the quality chasm: steps you can take. Trustee. 2001;54:30 2. 412. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collabo- ration. Lancet. 1994;344:563 70. 413. Nikolsky E, Gruberg L, Patil CV, et al. Percutaneous coronary inter- ventions in diabetic patients: is complete revascularization important? J Invasive Cardiol. 2004;16:102 6. 414. Osswald BR, Tochtermann U, Schweiger P, et al. Does the com- pleteness of revascularization contribute to an improved early survival in patients up to 70 years of age? Thorac Cardiovasc Surg. 2001;49: 373 7. 415. Kleisli T, Cheng W, Jacobs MJ, et al. In the current era, complete revascularization improves survival after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2005;129:1283 91. 416. Kozower BD, Moon MR, Barner HB, et al. Impact of complete revas- cularization on long-term survival after coronary artery bypass grafting in octogenarians. Ann Thorac Surg. 2005;80:112 6. 417. McLellan CS, Ghali WA, Labinaz M, et al. Association between completeness of percutaneous coronary revascularization and postpro- cedure outcomes. Am Heart J. 2005;150:800 6. 418. Wenaweser P, Surmely JF, Windecker S, et al. Prognostic value of early exercise testing after coronary stent implantation. Am J Cardiol. 2008;101:807 11. 419. Martuscelli E, Clementi F, Gallagher MM, et al. Revascularization strategy in patients with multivessel disease and a major vessel chron- ically occluded; data from the CABRI trial. Eur J Cardiothorac Surg. 2008;33:4 8. 420. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927 36. 421. Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolar- ization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289 93. 422. Holmes DR Jr, Gersh BJ, Whitlow P, et al. Percutaneous coronary intervention for chronic stable angina: a reassessment. J Am Coll Cardiol Intv. 2008;1:34 43. 423. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306:53 61. 424. Poses RM, Krueger JI, Sloman S, et al. Physicians judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease. Chest. 2002;122:122 33. 425. Holmboe ES, Fiellin DA, Cusanelli E, et al. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. J Gen Intern Med. 2000;15:632 7. 426. Lin GA, Dudley RA, Redberg RF. Cardiologists use of percutaneous coronary interventions for stable coronary artery disease. Arch Intern Med. 2007;167:1604 9. 427. Ko DT, Wang Y, Alter DA, et al. Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction. J Am Coll Cardiol. 2008;51:716 23. 428. Fisher E, Goodman D, Skinner J, et al. Health care spending, quality, and outcomes: more isn t always better: a topic brief by the Dartmouth AtlasofHealthCareProject.http://www.dartmouthatlas.org/downloads/ reports/Spending_Brief_022709.pdf. 2009. Accessed January 6, 2012. 429. Charatan F. Dozens of patients allege unnecessary heart surgery. BMJ. 2003;326:1055. 430. Fred HL. Dishonesty in medicine revisited. Tex Heart Inst J. 2008; 35:6 15. 431. Nallamothu BK, Rogers MA, Chernew ME, et al. Opening of specialty cardiac hospitals and use of coronary revascularization in medicare beneficiaries. JAMA. 2007;297:962 8. 432. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54: 522 3. 433. The Criteria Committee of the New York Heart Association I. Diseases of the heart and blood vessels: nomenclature and critera for diagnosis. 6th ed. Boston: Little, Brown; 1964. 434. Spertus JA, Eagle KA, Krumholz HM, et al. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147 56. 435. Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994;74: 1240 4. 436. Drozda J Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foun- dation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Con- sortium for Performance Improvement. Circulation. 2011;124: 248 70. 437. McGillion M, Watt-Watson J, LeFort S, et al. Positive shifts in the perceived meaning of cardiac pain following a psychoeducation program for chronic stable angina. Can J Nurs Res. 2007;39:48 65. 438. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62:338 51. 439. Rao SV, Schulman KA, Curtis LH, et al. Socioeconomic status and outcome following acute myocardial infarction in elderly patients. Arch Intern Med. 2004;164:1128 33. 440. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. Circulation. 2011; 123:1243 62. 441. Joint Commission. The Joint Commission announces the 2008 National Patient Safety Goals and Requirements. Jt Comm Perspect. 2007;27: 1,9 1,22. 442. Miller NH, Taylor C. Lifestyle Management for Patients with Coronary Heart Disease. (Current Issues in Cardiac Rehabilitation, Monograph No. 2.). 1st ed. Champaign, IL: Human Kinetics; 1995. 443. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721 9. 444. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89: 975 90. 445. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recom- mendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82 96. 446. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovas- cular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcom- mittee on Physical Activity). Circulation. 2003;107:3109 16. 447. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Car- diology. Circulation. 2007;115:2358 68. 448. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovas- cular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:406 41. 449. National Institutes of Health, National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. http:// www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. 1998. Accessed January 6, 2012. 450. Oka R, Kobayashi J, Yagi K, et al. Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract. 2008;79:474 81. Fihn et al Stable Ischemic Heart Disease: Full Text e445 451. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182 6. 452. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of car- diovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114 26. 453. Bosworth HB, Olsen MK, Dudley T, et al. The Take Control of Your Blood pressure (TCYB) study: study design and methodology. Contemp Clin Trials. 2007;28:33 47. 454. The 2004 United States Surgeon General s Report: The Health Con- sequences of Smoking. N S W Public Health Bull. 2004;15:107. 455. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86 97. 456. Standards of medical care in diabetes 2011. Diabetes Care. 2011;34 Suppl 1:S11 S61. 457. Appel LJ, Champagne CM, Harsha DW, et al. Effects of compre- hensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083 93. 458. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 1670 81. 459. Frattaroli J, Weidner G, Merritt-Worden TA, et al. Angina pectoris and atherosclerotic risk factors in the multisite cardiac lifestyle intervention program. Am J Cardiol. 2008;101:911 8. 460. Carney RM, Freedland KE, Eisen SA, et al. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88 90. 461. Rees K, Bennett P, West R, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2004;CD002902. 462. Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med. 2000;160:1818 23. 463. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of cita- lopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367 79. 464. McManus D, Pipkin SS, Whooley MA. Screening for depression in patients with coronary heart disease (data from the Heart and Soul Study). Am J Cardiol. 2005;96:1076 81. 465. Deleted in proof. 466. Deleted in proof. 467. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA. 2006;295:2874 81. 468. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and Coronary Heart Disease. Recommendations for Screening, Referral, and Treatment. A Science Advisory From the American Heart Asso- ciation Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2008;118:1768 75. 469. Patient education. American Academy of Family Physicians. Am Fam Physician. 2000;62:1712 4. 470. Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. Rockville (MD): US Department of Health and Human Services. 2008. Available at: http://www.ncbi.nlm. 2012. 471. Smith PM, Taylor CB. Implementing an Inpatient Smoking Cessation Program. Lawrence Erlbaum Associates, Inc.: 2006. 472. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343 50. 473. Kok G, van den Borne B, Mullen PD. Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness. Patient Educ Couns. 1997;30:19 27. 474. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182. 475. American Heart Association. AHA Choose to Move. American Heart Association. 2008. Available at: http://www.choosetomove.org. Accessed June 24, 2008. 476. Miller W, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York: Guilford; 2002. 477. Bandura A, Cervone D. Self-evaluative and self-efficacy mechanisms governing the motivational effects of goal systems. J Pers Soc Psych. 1983;45:1017 28. 478. Prochaska J, Norcross J, DiClemente C. Changing for Good: A Rev- olutionary Six Stage Program for Overcoming Bad Habits and Moving Your Life Positively Forward. New York: Avon Books, Inc.; 1984. 479. Coleman K, Austin BT, Brach C, et al. Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood). 2009;28:75 85. 480. Dorr DA, Wilcox AB, Brunker CP, et al. The effect of technologysup- ported, multidisease care management on the mortality and hospital- ization of seniors. J Am Geriatr Soc. 2008;56:2195 202. 481. Reid RJ, Fishman PA, Yu O, et al. Patient-centered medical home demonstration: a prospective, quasi-experimental, before and after evaluation. Am J Manag Care. 2009;15:e71 e87. 482. Bohlen JG, Held JP, Sanderson MO, et al. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745 8. 483. Moller J, Ahlbom A, Hulting J, et al. Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart. 2001;86:387 90. 484. Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol. 2000;86:14F 8F. 485. Ebrahim S, May M, Ben Shlomo Y, et al. Sexual intercourse and risk of ischaemic stroke and coronary heart disease: the Caerphilly study. J Epidemiol Community Health. 2002;56:99 102. 486. Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA. 2011;305:1225 33. 487. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol. 2005;96: 24M 8M. 488. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hyper- tension Study (TOMHS). Hypertension. 1997;29:8 14. 489. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65:773 86. 490. Franzen D, Metha A, Seifert N, et al. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, ran- domized and double blinded study. Int J Impot Res. 2001;13:348 51. 491. Baumhakel M, Schlimmer N, Kratz M, et al. Cardiovascular risk, drugs and erectile function a systematic analysis. Int J Clin Pract. 2011;65: 289 98. 492. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351 7. 493. Padma-nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology. 2002;60:67 90. 494. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45:339 44. 495. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, dox- azosin and tamsulosin in healthy normotensive men. J Urol. 2004; 172:1935 40. 496. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56: 320 8. 497. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18:441 9. 498. Schaefer EJ, Lamon-Fava S, Ausman LM, et al. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am J Clin Nutr. 1997;65:823 30. 499. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol. 1995;15:1079 85. 500. Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Choles- terol Education Program s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a metaanalysis. Am J Clin Nutr. 1999;69:632 46. 501. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437 45. 502. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251: 351 64. 503. Deleted in proof. 504. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245 55. 505. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, anti- oxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583 92. 506. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365 74. 507. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256: 2823 8. 508. Wilson PW, D Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: 1837 47. 509. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardio- vascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322: 1700 7. 510. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112 9. 511. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115:687 93. 512. Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus poli- cosanol. Pharmacotherapy. 2005;25:171 83. 513. Goldberg AC Ostlund RE Jr, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006;97:376 9. 514. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000;130:767 76. 515. Nguyen TT, Dale LC, von Bergmann K, et al. Cholesterollowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial. Mayo Clin Proc. 1999;74:1198 206. 516. Durstine JL, Grandjean PW, Cox CA, et al. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil. 2002;22:385 98. 517. Durstine JL, Grandjean PW, Davis PG, et al. Blood lipid and lipo- protein adaptations to exercise: a quantitative analysis. Sports Med. 2001;31:1033 62. 518. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33:S502 15. 519. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998 3007. 520. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. 521. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149 58. 522. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623 30. 523. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413 9. 524. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. Veterans Affairs High-Density Lipo- protein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410 8. 525. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289 98. 526. Whelton SP, He J, Whelton PK, et al. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol. 2004;93:1119 23. 527. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico. Lancet. 1999;354:447 55. 528. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 poly- unsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544 8. 529. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high- normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657 67. 530. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Col- laborative Research Group. Arch Intern Med. 1993;153:849 58. 531. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a ran- domized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998; 279:839 46. 532. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117 24. 533. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hyper- tension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3 10. 534. MacGregor GA, Markandu ND, Sagnella GA, et al. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet. 1989;2:1244 7. 535. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493 503. 536. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hyper- tension. 2001;38:1112 7. 537. Appel LJ, Frohlich ED, Hall JE, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascu- lar disease and stroke: a call to action from the American Heart Association. Circulation. 2011;123:1138 43. 538. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304:405 12. 539. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255 64. 540. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291: 97 104. 541. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-year findings of the hypertension detection and follow-up program. Hypertension. 1984;6:I198 I206. 542. The effect of treatment on mortality in mild hypertension: results of the hypertension detection and follow-up program. N Engl J Med. 1982;307:976 80. 543. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562 71. Fihn et al Stable Ischemic Heart Disease: Full Text e447 544. Major outcomes in high-risk hypertensive patients randomized to an- giotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981 97. 545. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527 35. 546. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. 547. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, editor. Textbook of Hyper- tension. Blackwell Scientific Publications; 1994. 548. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hyper- tension. 2003;42:878 84. 549. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Pre- vention, phase II. Ann Intern Med. 2001;134:1 11. 550. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16:761 70. 551. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. 552. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind com- parison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757 64. 553. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a sci- entific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761 88. 554. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggres- sively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884 93. 555. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563 74. 556. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010; 363:918 29. 557. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534 44. 558. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in pro- teinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349: 1857 63. 559. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342:821 8. 560. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investi- gators. N Engl J Med. 1991;325:293 302. 561. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333: 1670 6. 562. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hyper- tension. Arch Intern Med. 2002;162:1636 43. 563. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861 9. 564. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: 1667 75. 565. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephrop- athy due to type 2 diabetes. N Engl J Med. 2001;345:851 60. 566. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358: 1547 59. 567. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Com- mittees. Circulation. 1994;90:1765 73. 568. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707 14. 569. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN ran- domised trial. Lancet. 2001;357:1385 90. 570. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 8. 571. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Inter- vention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999;5:184 5. 572. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. 573. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Ran- domized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 17. 574. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977 86. 575. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837 53. 576. Patel A, MacMahon S, Chalmers J, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358:2560 72. 577. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med. 2008;358:2630 3. 578. Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360:129 39. 579. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643 53. 580. Effect of intensive blood-glucose control with metformin on compli- cations in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352: 854 65. 581. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO- active Study (PROspective pioglitAzone Clinical Trial In macro- Vascular Events): a randomised controlled trial. Lancet. 2005;366: 1279 89. 582. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351 7. 583. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394 403. 584. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070 80. 585. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52:2288 98. 586. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765 72. 587. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481 9. 588. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577 89. 589. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observa- tional studies. BMJ. 2011;342:1309. 590. Woodcock J. Center for Drug Evaluation and Research. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl) [Report NDA 021071]. 2010. Available at: http://www.fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM226959.pdf. Accessed January 15, 2011. 591. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and deter- minants of coronary artery disease in juvenile-onset, insulindependent diabetes mellitus. Am J Cardiol. 1987;59:750 5. 592. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23 000 patients with insulin-treated diabetes. Diabe- tologia. 2003;46:760 5. 593. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291 7. 594. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035 8. 595. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141 7. 596. Getz GS. Report on the workshop on diabetes and mechanisms of atherogenesis. September 17th and 18th, 1992, Bethesda, Maryland. Arterioscler Thromb. 1993;13:459 64. 597. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Partic- ipating Investigators and Staff. J Am Coll Cardiol. 1993;22:1141 54. 598. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term inten- sified insulin treatment on the development of microvascular compli- cations of diabetes mellitus. N Engl J Med. 1993;329:304 9. 599. McCormack J, Greenhalgh T. Seeing what you want to see in ran- domised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ. 2000;320:1720 3. 600. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545 59. 601. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383 93. 602. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta- analysis of randomized controlled trials. Am J Med. 2004;116:682 92. 603. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1081 93. 604. US Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Washington, DC: 2008. 605. Ken-Dror G, Lerman Y, Segev S, et al. [Development of a Hebrew questionnaire to be used in epidemiological studies to assess physical fitness validation against sub maximal stress test and predicted VO2max]. Harefuah. 2004;143:566 72, 623. 606. Cardinal BJ. Predicting cardiorespiratory fitness without exercise testing in epidemiologic studies: a concurrent validity study. J Epi- demiol. 1996;6:31 5. 607. Nowak Z, Plewa M, Skowron M, et al. Paffenbarger Physical Activity Questionnaire as an additional tool in clinical assessment of patients with coronary artery disease treated with angioplasty. Kardiol Pol. 2010;68:32 9. 608. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing cardiorespiratory fitness without performing exercise testing. Am J Prev Med. 2005;29: 185 93. 609. Taylor RS, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews CD007130. 2010. Accessed January 6, 2012. 610. Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2010;17:261 70. 611. McCartney N, McKelvie RS, Haslam DR, et al. Usefulness of weight- lifting training in improving strength and maximal power output in coronary artery disease. Am J Cardiol. 1991;67:939 45. 612. Beniamini Y, Rubenstein JJ, Faigenbaum AD, et al. High-intensity strength training of patients enrolled in an outpatient cardiac rehabili- tation program. J Cardiopulm Rehabil. 1999;19:8 17. 613. Centers for Disease Control and Prevention. 2008 Physical Activity Guidelines. cdc.gov. 2008. Available at: http://www.cdc.gov/ physicalactivity/everyone/guidelines/. Accessed May 20, 2010. 614. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 update: performance measures on cardiac rehabilitation for referral to cardiac rehabilitation/secondary prevention services: a report of the American Association of Cardiovascular and Pulmonary Rehabilitation and the American College of Cardiology Foundation/American Heart Asso- ciation Task Force on Performance Measures (Writing Committee to Develop Clinical Performance Measures for Cardiac Rehabilitation). Circulation. 2010;122:1342 50. 615. Froelicher V, Jensen D, Genter F, et al. A randomized trial of exercise training in patients with coronary heart disease. JAMA. 1984;252: 1291 7. 616. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary ath- erosclerotic lesions. J Am Coll Cardiol. 1993;22:468 77. 617. May GA, Nagle FJ. Changes in rate-pressure product with physical training of individuals with coronary artery disease. Phys Ther. 1984; 64:1361 6. 618. Oldridge NB, McCartney N, Hicks A, et al. Improvement in maximal isokinetic cycle ergometry with cardiac rehabilitation. Med Sci Sports Exerc. 1989;21:308 12. 619. Ornish D, Scherwitz LW, Doody RS, et al. Effects of stress man- agement training and dietary changes in treating ischemic heart disease. JAMA. 1983;249:54 9. 620. Sebrechts CP, Klein JL, Ahnve S, et al. Myocardial perfusion changes following 1 year of exercise training assessed by thallium-201 circum- ferential count profiles. Am Heart J. 1986;112:1217 26. 621. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86:1 11. 622. Todd IC, Ballantyne D. Effect of exercise training on the total ischaemic burden: an assessment by 24 hour ambulatory electrocardio- graphic monitoring. Br Heart J. 1992;68:560 6. 623. Rauramaa R, Li G, Vaisanen SB. Dose-response and coagulation and hemostatic factors. Med Sci Sports Exerc. 2001;33:S516 S520. 624. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43:1056 61. 625. Blumenthal JA, Sherwood A, Babyak MA, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005;293:1626 34. 626. Hambrecht R, Adams V, Erbs S, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107:3152 8. 627. Hosokawa S, Hiasa Y, Takahashi T, et al. Effect of regular exercise on coronary endothelial function in patients with recent myocardial infarction. Circ J. 2003;67:221 4. 628. Goldsmith RL, Bloomfield DM, Rosenwinkel ET. Exercise and autonomic function. Coron Artery Dis. 2000;11:129 35. 629. Malfatto G, Blengino S, Annoni L, et al. Original articles primary coronary angioplasty and subsequent cardiovascular rehabilitation are linked to a favorable sympathovagal balance after a first anterior myocardial infarction. Ital Heart J. 2005;6:21 7. 630. Digenio AG, Sim JG, Dowdeswell RJ, et al. Exercise-related cardiac arrest in cardiac rehabilitation. The Johannesburg experience. S Afr Med J. 1991;79:188 91. 631. Franklin BA, Bonzheim K, Gordon S, et al. Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16-year follow-up. Chest. 1998;114:902 6. 632. Van Camp SP, Peterson RA. Cardiovascular complications of out- patient cardiac rehabilitation programs. JAMA. 1986;256:1160 3. 633. Vongvanich P, Paul-Labrador MJ, Merz CN. Safety of medically supervised exercise in a cardiac rehabilitation center. Am J Cardiol. 1996;77:1383 5. 634. Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1993;831:1 122. Fihn et al Stable Ischemic Heart Disease: Full Text e449 635. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly inde- pendent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167:1720 8. 636. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for profes- sionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2004;110:2952 67. 637. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341: 1097 105. 638. Jensen MK, Chiuve SE, Rimm EB, et al. Obesity, behavioral lifestyle factors, and risk of acute coronary events. Circulation. 2008;117: 3062 9. 639. Arnlov J, Ingelsson E, Sundstrom J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230 6. 640. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925 32. 641. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39: 578 84. 642. Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med. 2010;170: 1293 301. 643. Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor. Int J Obes Relat Metab Disord. 1995;19:585 9. 644. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middleaged and older US men. Am J Epidemiol. 1995;141:1117 27. 645. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA. 2006;296: 79 86. 646. Pi-Sunyer FX. The obesity epidemic: pathophysiology and conse- quences of obesity. Obes Res. 2002;10 Suppl 2:97S 104S. 647. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666 78. 648. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357: 741 52. 649. Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, et al. 